Henlius advances cetuximab biosimilar toward the U.S. market: full analysis
Henlius is moving another biosimilar candidate into the U.S. regulatory pathway, with trade coverage reporting that the FDA has cleared an investigational new drug application for HLX05-N, the company’s biosimilar candidate to Erbitux (cetuximab). The update fits a broader pattern for the Shanghai-based developer, which has been steadily building a global oncology and biosimilar portfolio, including recent U.S. progress for other pipeline assets and marketed biosimilars. (www1.hkexnews.hk)
The immediate backdrop is Henlius’ April 14, 2026, announcement that China’s National Medical Products Administration approved a phase 1 IND for HLX05-N in metastatic colorectal cancer. In that announcement, and again in its 2025 annual report filed later in April, Henlius said HLX05-N is a cetuximab biosimilar and that it intends to launch an international multicenter phase 1 study once conditions are met. The annual report also places HLX05-N within a larger development engine that has recently produced multiple U.S. IND clearances across oncology programs. (henlius.com)
Henlius describes HLX05-N as a recombinant anti-EGFR chimeric monoclonal antibody biosimilar intended for colorectal cancer and head and neck squamous cell carcinoma. Cetuximab itself is an established EGFR-targeted therapy, and the National Cancer Institute lists it as an FDA-approved treatment used in colorectal cancer and certain head and neck cancers. Henlius’ disclosures, however, indicate the current clinical focus for HLX05-N is metastatic colorectal cancer, at least at this stage of development. (www1.hkexnews.hk)
What’s notable is the market context. FDA’s biosimilar product information page does not list a cetuximab biosimilar among approved U.S. products, suggesting the reference category remains open. That matters because cetuximab has been discussed for years as a likely biosimilar target in oncology, but actual U.S. competition has lagged behind more mature biosimilar classes such as trastuzumab, bevacizumab, and rituximab. In that sense, HLX05-N looks less like a me-too filing and more like an attempt to enter a gap in the current U.S. biosimilar landscape. This last point is an inference based on FDA’s current biosimilar listings and Henlius’ pipeline disclosures. (fda.gov)
Expert reaction specific to HLX05-N appears limited so far, which is common at the IND-clearance stage. But the broader oncology biosimilar conversation is well established. FDA says biosimilars can create more treatment options and may cost less because developers can rely in part on the agency’s prior finding that the reference biologic is safe and effective. Reviews and expert commentary in oncology have similarly emphasized that the promise of biosimilars is tied not just to approval, but to clinician confidence, payer dynamics, education, and operational uptake. (fda.gov)
Why it matters: For veterinary professionals, this isn’t about near-term changes in companion animal oncology protocols. It matters more as a readout on where biologics competition is heading. Large animal health and companion animal medicine increasingly intersect with the same manufacturing, supply chain, regulatory, and reimbursement ecosystems that shape human biologics. A company that successfully expands its U.S. biosimilar footprint can gain manufacturing leverage, regulatory credibility, and commercial experience that may ripple outward across adjacent biologics markets. More broadly, the story reinforces how oncology remains one of the key proving grounds for biosimilar competition. (www1.hkexnews.hk)
Henlius also has reason to keep pushing in the U.S. The company’s annual report highlights recent FDA milestones for other candidates and notes that its pertuzumab biosimilar HLX11 was approved in the United States in November 2025 under the trade name Poherdy. That suggests Henlius is no longer approaching the U.S. as a distant opportunity, but as an active strategic market for both development-stage and commercial-stage biosimilars. (www1.hkexnews.hk)
What to watch: The next signals will be practical ones: whether Henlius publicly confirms the FDA IND clearance directly, when the international phase 1 study opens, where sites are located, whether U.S. patients are enrolled early, and whether the company names any commercialization or co-development partner for HLX05-N. If the program advances cleanly, the bigger question will be whether it can become one of the first cetuximab biosimilars to reach the U.S. market. (www1.hkexnews.hk)